Innovation1 Biotech Inc. (IVBT)

USD 0.0

(400.0%)

Total Liabilities Summary of Innovation1 Biotech Inc.

Innovation1 Biotech Inc.'s latest annual total liabilities in 2023 was 3.5 Million USD , down -91.47% from previous year.
Innovation1 Biotech Inc.'s latest quarterly total liabilities in 2023 FY was 3.5 Million USD , down -91.47% from previous quarter.
Innovation1 Biotech Inc. reported annual total liabilities of 41.11 Million USD in 2022, up 10007.77% from previous year.
Innovation1 Biotech Inc. reported annual total liabilities of 406.72 Thousand USD in 2021, down -85.91% from previous year.
Innovation1 Biotech Inc. reported quarterly total liabilities of 3.5 Million USD for 2023 FY, down -91.47% from previous quarter.
Innovation1 Biotech Inc. reported quarterly total liabilities of 3.5 Million USD for 2023 Q4, up 34.6% from previous quarter.

Annual Total Liabilities Chart of Innovation1 Biotech Inc. (2023 - 2015)

Historical Annual Total Liabilities of Innovation1 Biotech Inc. (2023 - 2015)

Year	Total Liabilities	Total Liabilities Growth
2023	3.5 Million USD	-91.47%
2022	41.11 Million USD	10007.77%
2021	406.72 Thousand USD	-85.91%
2020	2.88 Million USD	1188.36%
2019	224.05 Thousand USD	-67.38%
2018	686.86 Thousand USD	795.75%
2017	76.68 Thousand USD	55.9%
2016	49.18 Thousand USD	259.63%
2015	13.67 Thousand USD	0.0%

Year	Total Liabilities	Total Liabilities Growth
2023 Q1	2.35 Million USD	9.04%
2023 FY	3.5 Million USD	-91.47%
2023 Q4	3.5 Million USD	34.6%
2023 Q3	2.6 Million USD	0.0%
2023 Q2	2.6 Million USD	10.49%
2022 Q3	40.89 Million USD	0.53%
2022 Q1	40.32 Million USD	9814.66%
2022 FY	41.11 Million USD	10007.77%
2022 Q2	40.67 Million USD	0.87%
2022 Q4	2.16 Million USD	-94.71%
2021 Q2	2.52 Million USD	-19.15%
2021 Q4	406.72 Thousand USD	286.35%
2021 FY	406.72 Thousand USD	-85.91%
2021 Q3	105.27 Thousand USD	-95.82%
2021 Q1	3.11 Million USD	8.02%
2020 Q1	619.89 Thousand USD	176.67%
2020 FY	2.88 Million USD	1188.36%
2020 Q4	2.88 Million USD	11.83%
2020 Q3	2.58 Million USD	-0.9%
2020 Q2	2.6 Million USD	320.19%
2019 Q1	531.1 Thousand USD	-22.68%
2019 FY	224.05 Thousand USD	-67.38%
2019 Q4	224.05 Thousand USD	-11.13%
2019 Q3	252.1 Thousand USD	-34.0%
2019 Q2	381.99 Thousand USD	-28.08%
2018 Q4	686.86 Thousand USD	326.38%
2018 FY	686.86 Thousand USD	795.75%
2018 Q3	161.09 Thousand USD	15.48%
2018 Q1	112.07 Thousand USD	46.16%
2018 Q2	139.49 Thousand USD	24.47%
2017 FY	76.68 Thousand USD	55.9%
2017 Q1	56.56 Thousand USD	14.99%
2017 Q3	65.16 Thousand USD	6.86%
2017 Q2	60.97 Thousand USD	7.81%
2017 Q4	76.68 Thousand USD	17.67%
2016 Q1	24.79 Thousand USD	81.25%
2016 Q4	49.18 Thousand USD	16.59%
2016 Q3	42.18 Thousand USD	55.23%
2016 Q2	27.17 Thousand USD	9.63%
2016 FY	49.18 Thousand USD	259.63%
2015 FY	13.67 Thousand USD	0.0%
2015 Q4	13.67 Thousand USD	0.0%

Peer Total Liabilities Comparison of Innovation1 Biotech Inc.

Name	Total Liabilities	Total Liabilities Difference
America Great Health	4.82 Million USD	27.337%
Gene Biotherapeutics, Inc.	- USD	-Infinity%
Evolutionary Genomics, Inc.	7.94 Million USD	55.875%
Point of Care Nano-Technology, Inc.	266.41 Thousand USD	-1215.98%
Vicapsys Life Sciences, Inc.	1.96 Million USD	-78.118%